Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead Sciences (GILD). The latter "offers 15-20% upside and the most attractive combination of fundamental positive drivers... 2012 events have the potential to meaningfully improve long-term cash flow visibility, driving multiple expansion and positive EPS revisions.”